RPB0391

Pathogen Description

Target Pathogen Pathogen Name NCBI Taxonomy ID Order Family Genus Species Pathogen type
SARS-CoV-2 SARS-CoV-2, 2019-nCoV, COVID-19, COVID-19 virus, SARS2, Wuhan coronavirus, Human coronavirus 2019, COVID19, HCoV-19, SARS-2, SARS-CoV4 2697049 Nidovirales Coronaviridae Betacoronavirus Severe acute respiratory syndrome-related coronavirus virus

Primer Description

Primer Name Sequence(5'-3') Length(bp) Primer Final Concentration(μM) GC Content(%) Predicted Melting Temperature(℃) Molecular Weight(g/moles) Positions in GenBank accession number
M1-BbsI-F ATGGCAGATTCAACGGTACTATTACCGTT 29 \ 41.38 59.31 8891.85 \
M1-BbsI-R CCTACAAGACAAGCCATTGCGATAGCAATT 30 \ 43.33 60.81 9168.05 \

Gene Description

Target Gene GenBank ID
BbsI \

Assay Description

Application Assay Primer Designing Software Reaction Time(min) Assay Temperature(℃) Readout System(s) Limit of Detection(LoD) Sensitivity(%) Specificity(%)
accurate, specific, sensitive, simple, rapid, equipment-free, and provide deliverables to the end-users RPA- CRISPRCas9 \ 10 min 39°C CRISPRCas9 75 ng \ \

Publication Description

Year of Publication Title Author(s) Journal PMID DOI
2023 A CRISPR-based approach using dead Cas9-sgRNA to detect SARS-CoV-2 Mustapha Aouida,Maryam Saifaldeen,Dana E Al-Ansari,Sara Taleb,Ali Ait Hssain,Dindial Ramotar Frontiers in Molecular Biosciences 37388245 10.3389/fmolb.2023.1201347

A CRISPR-based approach using dead Cas9-sgRNA to detect SARS-CoV-2

Author(s):

Mustapha Aouida,Maryam Saifaldeen,Dana E Al-Ansari,Sara Taleb,Ali Ait Hssain,Dindial Ramotar

Journal:

Frontiers in Molecular Biosciences

Year:

2023

Abstract:

Rapid, highly specific, and robust diagnostic kits to detect viruses and pathogens are needed to control disease spread and transmission globally. Of the many different methods proposed to diagnose COVID-19 infection, CRISPR-based detection of nucleic acids tests are among the most prominent. Here, we describe a new way of using CRISPR/Cas systems as a rapid and highly specific tool to detect the SARS-CoV-2 virus using the in vitro dCas9-sgRNA-based technique. As a proof of concept, we used a synthetic DNA of the M gene, one of the SARS-CoV-2 virus genes, and demonstrated that we can specifically inactivate unique restriction enzyme sites on this gene using CRISPR/Cas multiplexing of dCas9-sgRNA-BbsI and dCas9-sgRNA-XbaI. These complexes recognize and bind to the target sequence spanning the BbsI and XbaI restriction enzyme sites, respectively, and protect the M gene from digestion by BbsI and/or XbaI. We further demonstrated that this approach can be used to detect the M gene when expressed in human cells and from individuals infected with SARS-CoV-2. We refer to this approach as dead Cas9 Protects Restriction Enzyme Sites, and believe that it has the potential to be applied as a diagnostic tool for many DNA/RNA pathogens.